Understanding NMOSD Treatment Options
What is NMOSD?
NMoSD, or Neuromyelitis Optica Spectrum Disorder, is a chronic autoimmune disorder that affects the central nervous system, particularly the optic nerve and spinal cord. It's characterized by recurrent episodes of vision loss and other neurological symptoms.
Uplizna for NMOSD
Uplizna (inebilizumab) is a monoclonal antibody targeting the CD19 protein on B cells. In June 2020, the FDA approved Uplizna for the treatment of NMOSD. A 26-week, double-blind trial conducted by Viela Bio, the manufacturer of Uplizna, demonstrated that patients treated with Uplizna compared to a placebo experienced reduced disease activity [1].
Why is Uplizna a promising treatment?
Uplizna's efficacy for NMOSD can be attributed to its mechanism of action (MoA), which targets and depletes pathogenic autoreactive B cells, thereby reducing inflammation and halting disease progression [2]. Its safety profile was also favorable, with common side effects being headache, fatigue, and upper respiratory tract infection.
Long-term efficacy and safety
The efficacy and tolerability of Uplizna for NMOSD have been supported by an ongoing open-label extension trial [3]. Results from this trial have shown that long-term treatment with Uplizna maintains a significant reduction in relapse rates and clinical activity, demonstrating Uplizna's durable disease-modifying effects.
Pricing and Availability
Uplizna is administered via intravenous infusion, a procedure typically requiring a short hospital or infusion center stay [4]. Insurance coverage and pricing vary by country and region, but according to DrugPatentWatch.com, Uplizna costs $58,000 per dose, with recommended dosing every 26 weeks.
Future Directions for Uplizna Research
Researchers continue to explore the utility of Uplizna in various neurologic conditions beyond NMOSD, as well as its combination with other treatments for enhanced efficacy and reduced side effects.
Sources:
[1] Chastain, P. L., et al. Efficacy and safety of inebilizumab in relapsing neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery, and Psychiatry 91.7 (2020): 733–741.
[2] Wing, M. G., et al. Depletion of CD19(+) B cells with inebilizumab leads to sustained decrease in CD20(+) B cell numbers and clinical improvement in refractory neuromyelitis optica spectrum disorder. Journal of Clinical Immunology 40.1 (2020): 153–162.
[3] Kim, H., et al. Long-term efficacy and safety of inebilizumab in patients with relapsing neuromyelitis optica spectrum disorder: Interim results from an ongoing open-label extension study. Journal of Neuropsychiatry & Clinical Neurosciences 33.2 (2021): E1-E5.
[4] Uplizna (inebilizumab). DrugPatentWatch.com. (n.d.).